Core Points - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. on behalf of investors who purchased its common stock during its initial public offering around September 15, 2023 [1] - The lead plaintiff deadline for the lawsuit is set for April 7, 2025 [1] Allegations Against Defendants - The complaint alleges that Neumora made materially false and misleading statements in its Offering Documents, including the need to amend Phase Two Trial inclusion criteria to justify its Phase Three Program [2] - It is claimed that Neumora added a prespecified analysis to the Phase Two statistical analysis plan focusing on patients with moderate to severe major depressive disorder [2] - The Phase Two Trials reportedly lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [2] Lead Plaintiff Process - Investors in Neumora can seek to be appointed as a lead plaintiff representative of the class by April 7, 2025, or may choose to remain absent [3] - The lead plaintiff acts on behalf of all class members and selects counsel to represent the class [3] - Participation as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3] Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has recovered billions for victims of corporate misconduct [4] - The firm encourages Neumora investors who have suffered losses to contact them for more information [4]

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud affecting investors who purchased its common stock since September 15, 2023 [1][2]. Class Definition - The lawsuit aims to recover losses for all individuals or entities that acquired Neumora common stock based on the Offering Documents [2]. Case Details - The complaint alleges that Neumora made false statements and concealed critical information regarding its Phase Three Program and Phase Two Trials, including: 1. Amendments to the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to demonstrate the efficacy of Navacaprant [3]. 2. Addition of a prespecified analysis in the Phase Two statistical analysis plan focusing on moderate to severe MDD patients [3]. 3. Insufficient data in the Phase Two Trials, particularly regarding patient population size and gender ratio, which undermined the ability to predict outcomes of the KOASTAL-1 study [3]. Next Steps - Investors who suffered losses during the relevant timeframe have until April 7, 2025, to request appointment as lead plaintiff, although participation does not require this role [4]. No Cost to Participants - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [4]. Why Levi & Korsinsky - The firm has a strong track record in securities litigation, having secured hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the U.S. [5].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a securities class action lawsuit related to its September 2023 IPO, with a lead plaintiff deadline set for April 7, 2025 [1][3]. Group 1: Class Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6]. - The lawsuit alleges that the Offering Documents contained false or misleading statements regarding the Phase Two Trials and their implications for the Phase Three Program [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]. - Investors are advised that until a class is certified, they are not represented unless they retain counsel [7].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding its clinical trials and the efficacy of its flagship therapeutic candidate, Navacaprant [2][3]. Group 1: Allegations - The lawsuit claims that Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [2]. - It is alleged that the company added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2]. - The complaint also states that the Phase Two Trials lacked adequate data, particularly concerning the patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [2]. Group 2: Class Action Details - The class period for the lawsuit commenced on or about September 15, 2023, and shareholders who purchased shares during this time are encouraged to register [1][3]. - The deadline for shareholders to seek lead plaintiff status is April 7, 2025, and there is no cost or obligation to participate in the case [3]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

Core Points - A class action has been filed against Neumora Therapeutics, Inc. on behalf of investors who purchased shares during the IPO on September 15, 2023 [1] - The allegations claim that Neumora misled investors regarding the prospects of its flagship candidate, Navacaprant, for treating major depressive disorder (MDD) [2][3] - Following the announcement of disappointing results from the KOASTAL-1 study on January 2, 2025, Neumora's stock price plummeted from $17 to $1.91, representing an 88.7% decline [3] Allegations - The Offering Documents allegedly failed to disclose critical information about Navacaprant's Phase Two Trial, including amendments to inclusion criteria and inadequate data regarding patient demographics [2] - The complaint highlights that the Phase Two Trials did not provide sufficient data to predict the outcomes of the subsequent KOASTAL-1 study [2] Stock Performance - Neumora's common stock has seen a significant decline since the IPO, dropping from an initial price of $17 per share to $1.91 per share by February 5, 2025 [3] Legal Proceedings - Shareholders interested in participating as lead plaintiffs in the class action must file by April 7, 2025 [4] - The representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]

Core Viewpoint - A class action lawsuit has been filed against Neumora Therapeutics, Inc. for alleged securities fraud and unlawful business practices following disappointing clinical trial results [2][4]. Group 1: Lawsuit Details - The class action lawsuit is initiated by investors who believe Neumora and its officers engaged in securities fraud [2]. - Investors have until April 7, 2025, to request appointment as Lead Plaintiff if they purchased Neumora securities during the Class Period [3]. Group 2: Company Performance and Events - Neumora conducted its initial public offering (IPO) on September 15, 2023, selling 14.71 million shares at $17.00 per share [3]. - On January 2, 2025, Neumora announced the KOASTAL-1 study results for Navacaprant, which failed to show statistically significant improvement in key endpoints, leading to a significant stock price drop of $8.63, or 81.42%, closing at $1.97 per share [4].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud affecting investors who purchased its common stock since September 15, 2023 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Neumora Therapeutics, Inc. [2] - The complaint alleges that Neumora made false statements and concealed critical information regarding its Phase Three Program and the Phase Two trials of its flagship therapeutic candidate, Navacaprant [3]. - Specific allegations include the amendment of trial inclusion criteria to show statistically significant improvement in treating Major Depressive Disorder (MDD) and the addition of a prespecified analysis that lacked adequate data [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until April 7, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].

Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. for allegedly making materially false and misleading statements in its Offering Documents related to its initial public offering on September 15, 2023 [1] Group 1: Allegations Against Neumora - The lawsuit claims that Neumora amended its Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2] - It is alleged that Neumora added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2] - The complaint states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which affected the ability to predict results of the KOASTAL-1 study accurately [2] Group 2: Lead Plaintiff Process - Neumora investors can seek to be appointed as a lead plaintiff representative of the class by April 7, 2025, or may choose to remain absent [3] - A lead plaintiff acts on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [3] - The decision to serve as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3] Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages Neumora investors who have suffered losses to contact them for more information [4] - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4]

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit related to its IPO, alleging violations of the Securities Act of 1933 due to misleading information regarding its clinical trials and subsequent stock performance [1][3][4]. Company Overview - Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases [2]. - The company acquired its flagship therapeutic candidate, Navacaprant, through the acquisition of BlackThorn Therapeutics, Inc. in September 2020 [2]. IPO Details - Neumora conducted its initial public offering (IPO) on September 15, 2023, selling 14.7 million shares at a price of $17.00 per share [2]. - Following the IPO, the stock price has significantly declined, reaching a closing price of $1.91 per share on February 5, 2025, representing an 88.7% decrease from the IPO price [4]. Allegations in the Lawsuit - The lawsuit claims that the IPO offering documents were materially false and misleading, particularly regarding the Phase Two Trial inclusion criteria and the adequacy of data for predicting results in the KOASTAL-1 study [3]. - It is alleged that Neumora had to amend the original Phase Two Trial criteria to include a patient population with moderate to severe major depressive disorder to justify its Phase Three Program [3]. - The company disclosed on January 2, 2025, that the KOASTAL-1 study failed to show a statistically significant improvement on key endpoints, which contributed to the decline in stock value [4]. Legal Process - Investors who purchased Neumora common stock in connection with the IPO have until April 7, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][5]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [5].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements and inadequate data regarding its clinical trials, particularly related to its experimental depression treatment, navacaprant [4][5]. Group 1: Legal Actions and Investigations - Faruqi & Faruqi, LLP is investigating potential claims against Neumora and has set an April 7, 2025 deadline for investors to seek the role of lead plaintiff in the class action [2]. - Investors who suffered losses exceeding $50,000 in Neumora's IPO are encouraged to contact the firm to discuss their legal options [1]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora and its executives violated federal securities laws by making false statements and failing to disclose critical information about the Phase Two and Phase Three clinical trials [4]. - Specific allegations include the amendment of trial inclusion criteria to show statistically significant results and the lack of adequate data in the Phase Two Trials, which affected the predictability of the Phase III study results [4]. Group 3: Impact on Stock Performance - Following the announcement of the failure of navacaprant in the Phase III Koastal-1 trial, Neumora's stock price dropped by 81%, closing at $1.97 per share on January 2, 2025 [5].